Karen Aboody, M.D. 
Dr. Aboody, Professor at the Department of Developmental & Stem Cell Biology, received her MD from Mount Sinai School of Medicine. A major research focus of her laboratory is to modify and develop human neural stem cells into a novel therapeutic vehicle for delivering different cancer therapeutic agents to tumor sites in animal models.
Behnam Badie, M.D.
Dr. Badie, Vice Chair and Professor at the Department of Surgery, received his MD from UCLA.  Dr. Badie's research focuses on exploring novel immunotherapeutic strategies through the activation of microglia and macrophages to treat malignant brain tumors. He is also developing minimally invasive devices to deliver drugs into brain tumors.  
Daniela Castanotto, Ph.D.
Dr. Castanotto, Research Professor at the Department of Medical Oncology and Therapeutics Research, received her PhD from University of Messina, Italy. Dr. Castanotto’s research focuses on the development of technology to promote uptake and activity of oligonucleotides as a potential means of targeting genes and affecting expression.
Shiuan Chen, Ph.D. 
Dr. Chen, Chair of the Department of Cancer Biology, received his PhD from University of Hawaii. His team focuses on refining current treatment strategies and available drugs for better application against breast cancer. He also investigates how environmental chemicals and diet modulate the development of hormone-dependent cancers.
Wenyong Chen, Ph.D. 
Dr. Chen, Associate Professor at the Department of Cancer Biology, received his PhD from University of Alabama at Birmingham. His laboratory is interested in understanding epigenetic regulation of hematopoietic stem cell aging, leukemia development and drug resistance in leukemia stem cells.  
Don Diamond, Ph.D. 
Dr. Diamond, Professor at the Department of Immuno-Oncology, received his PhD from Harvard Medical School. His laboratory is focusing on developing a novel approach that uses attenuated salmonella encoding a short hairpin RNA to decrease the expression of molecules contributing to tumor rejection and controlling metastasis. 
David Horne, Ph.D. 
Dr. Horne, Vice Provost & Chair of the Department of Molecular Medicine, received his PhD from MIT. His team focuses on developing new synthetic methods and strategies for the total synthesis of architecturally complex, biologically active natural compounds and their analogs as potential novel therapeutic agents.
Wendong Huang, Ph.D. 
Dr. Huang, Professor at the Department of Diabetes Complications & Metabolism, received his PhD from University of Texas Houston. His team is interested in identifying the molecular pathways by a group of nuclear receptors in regulating metabolism and in the pathogenesis of diabetes and cancer.    
Michael Kahn, Ph.D. 
Dr. Kahn, Professor and Chair of the Department of Molecular Medicine, received his PhD from Yale University. His research team focuses on dissecting the signaling pathways in somatic and cancer stem cell development. Their second generation of CBP/-catenin antagonist is currently in the clinical trials for various cancers and liver fibrosis. 
Marcin Kortylewski, Ph.D. 
Dr. Kortylewski, Associate Professor at the Department of Immuno-Oncology, received his PhD from the University School of Medical Sciences, Poznan, Poland. His research is directed at developing a novel oligonucleotide approach to specifically target immune cells associated with tumors and attenuate STAT3's activity in promoting tumor growth.
Dan J. Raz. M.D., M.A.S.
Dr. Raz, Assistant Professor, Division of Thoracic Surgery, Department of Surgery specializes in lung cancer surgery. His laboratory is focused on targeting specific epigenetic marks to overcome therapy resistance in lung cancer. His laboratory is active in drug discovery and use of human lung cancer tissue to test new therapeutics including 3D cell culture, tissue slice culture, and patient derived xenografts.
Steven Rosen, M.D. 
Dr. Rosen, Provost & Professor at the Department of Hematology & Hematopoietic Cell Transplantation, received his MD from Northwestern University. His team is developing novel therapies for hematologic malignancy by targeting ATP synthase, dihydroorotate dehydrogenase, histone deacetylase and de-ubiquinase. 
John Rossi, Ph.D. 
Dr. Rossi, Chair of the Department of Molecular & Cellular Biology and Dean of Irell & Manella Graduate School of Biological Sciences, received his PhD from University of Connecticut. His laboratory focuses on developing RNA aptamers and cell internalizing delivery vehicle for the treatments of HIV infection and cancers. 
Timothy Synold, Pharm.D.
Dr. Synold, Professor of Cancer Biology and the Director of Analytic Pharmacology Core, received his PharmD from UCSF. In his numerous collaborations with City of Hope investigators, his team is responsible for the design and conduct of preclinical phase 1 and 2 pharmacokinetic investigations of anti-cancer agents.
John Williams, Ph.D. 
Dr. Williams, Professor at the Department of Molecular Medicine, received his PhD from Columbia University. His group utilizes X-ray crystallography and biophysical methods to design, quantify and optimize novel therapeutics, including monoclonal antibodies and STAT3 inhibitor, for cancer treatment.